

# If you have patients diagnosed with CIDP,

currently prescribed but not yet started  
treatment with **efgartigimod/Vyvgart®**  
**Hytrulo**, consider referring them to this  
real-world evidence (RWE) study.



We are recruiting about **120 adult participants for ADHERE REAL**, a prospective study that aims to assess the real-world effectiveness of efgartigimod in treating participants with CIDP, describe their “treatment journey”, and assess the use of health care services among adults who initiate treatment with **efgartigimod**.

Patients with CIDP that will be initiating **efgartigimod** treatment may be eligible. The study is observational, with fully remote follow-ups, and completing periodic questionnaires on quality of life, symptoms, and treatment experiences.

If you have eligible patients or you are interested in learning more, please send email to:  
[argxadhererealstudy.sm@thermofisher.com](mailto:argxadhererealstudy.sm@thermofisher.com)